Non-
Conditions
Interventions
Oligonol is a low molecular weight oligomer of long-
chain polyphenols from lychee extracts. ,Placebo
Experimental Dietary Supplement,Placebo Comparator No treatment
Oligonol,Placebo
Sponsors
AHCC (Thailand) co. Ltd.
Ratchadaphiseksomphot Endowment Fund
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adults aged 18 years and older with NAFLD were enrolled in the study. NAFLD was defined by elevated ALT (ALT ≥19 U/L in women and ≥30 U/L in men) with the presence of hepatic steatosis grade ≥2 (defined as liver fat content ≥11% by MRI-PDFF).
Exclusion criteria
Exclusion criteria: (1) cirrhosis defined by cirrhotic configuration on liver imaging or liver stiffness score ≥ 10.3 kPa on transient elastography (2) liver decompensation (defined by history of bleeding varices, ascites, and encephalopathy) (3) hepatocellular carcinoma (4) daily alcohol drinking >30 g in men, 20 g in women (5) other known chronic liver diseases, such as chronic hepatitis B, chronic hepatitis C, autoimmune hepatitis, primary biliary cholangitis, hemochromatosis, and Wilson disease (6) pregnancy (7) history of lychee allergy (8) chronic kidney disease stage 3 and above (calculated glomerular filtration rate <60 mL/min).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the reduction of hepatic fat content 6 months after the initiation of Oligonol Magnetic resonance imaging with proton density fat fraction | — |
Secondary
| Measure | Time frame |
|---|---|
| The improvement of metabolic syndrome 6 months after the initiation of Oligonol body mass index, blood pressure, insulin resistance, and serum lipids ,The reduction in oxidative stress, inflammation and apoptosis 6 months after the initiation of Oligonol Serum cytokerarin-18 fragment, Malondialdehyde | — |
Countries
Thailand
Contacts
Public ContactManeerat Chayanupatkul
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed